Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Texas Children's Hospital, Houston, Texas, United States
KK Women's and Children's Hospital, Singapore, Singapore
Virginia Mason Medical Center, Seattle, Washington, United States
Department of Anaesthesiology, Næstved, Danmark, Denmark
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
Changi General Hospital, Singapore, Singapore
Hillel Yaffe Medical Center, Hadera, Israel
Department of Anesthesiology,Sixth People's Hospital, Shanghai, Shanghai, China
Saint Barnabas Medical Center, Livingston, New Jersey, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.